Ash Bullement (A Bullement)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 25

Top Topics

Acute Lymphoblastic Leukemia

Systematic Review

Palliative Care

Metastatic Colorectal Cancer

Top Venues

PharmacoEconomics

Future oncology (London, England)

Applied health economics and health policy

This page only lists publications with an associated author ORCID identifier.

Publications

Sachin Vadgama, Marcelo C Pasquini, Richard T Maziarz, Zhen-Huan Hu, Markqayne Ray, Harry Smith, Ash Bullement, Mark Edmondson-Jones, Will Sullivan, Guillaume Cartron
"Don't keep me waiting": estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes. Blood advances 8 (13) (2024)
Sachin Vadgama, Marcelo C Pasquini, Richard T Maziarz, Zhen-Huan Hu, Markqayne Ray, Harry Smith, Ash Bullement, Mark Edmondson-Jones, Will Sullivan, Guillaume Cartron
"Don't keep me waiting": estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes. Blood advances 8 (13) (2024)
Sachin Vadgama, Richard T Maziarz, Marcelo C Pasquini, Zhen-Huan Hu, Markqayne D Ray, Harry Smith, Ash Bullement, Mark Edmondson-Jones, Will Sullivan, Guillaume Cartron
Don't keep me waiting: estimating the lifetime impact of reduced vein-to-vein time for CAR-T treated patients with LBCL. Blood advances (2024)
Gemma Elizabeth Shields, Paul Clarkson, Ash Bullement, Samuel Wagner, Mark Wilberforce, Tracey M Farragher, Arpana Verma, Linda M Davies
Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature. PharmacoEconomics 42 (7) (2024)
Ash Bullement, Mark Edmondson-Jones, Patricia Guyot, Nicky J Welton, Gianluca Baio, Matthew Stevenson, Nicholas R Latimer
MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation-A Tutorial. PharmacoEconomics (2024)
Sachin Vadgama, Richard T Maziarz, Marcelo C Pasquini, Zhen-Huan Hu, Markqayne D Ray, Harry Smith, Ash Bullement, Mark Edmondson-Jones, Will Sullivan, Guillaume Cartron
Don't keep me waiting: estimating the lifetime impact of reduced vein-to-vein time for CAR-T treated patients with LBCL. Blood advances (2024)
Gemma Elizabeth Shields, Paul Clarkson, Ash Bullement, Samuel Wagner, Mark Wilberforce, Tracey M Farragher, Arpana Verma, Linda M Davies
Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature. PharmacoEconomics 42 (7) (2024)
Gemma Elizabeth Shields, Paul Clarkson, Ash Bullement, Samuel Wagner, Mark Wilberforce, Tracey M Farragher, Arpana Verma, Linda M Davies
Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature. PharmacoEconomics 42 (7) (2024)
Sachin Vadgama, Marcelo C Pasquini, Richard T Maziarz, Zhen-Huan Hu, Markqayne D Ray, Harry Smith, Ash Bullement, Mark Edmondson-Jones, Will Sullivan, Guillaume Cartron
Don't keep me waiting: estimating the lifetime impact of reduced vein-to-vein time for CAR-T treated patients with LBCL. Blood advances (2024)
Sachin Vadgama, Marcelo C Pasquini, Richard T Maziarz, Zhen-Huan Hu, Markqayne Ray, Harry Smith, Ash Bullement, Mark Edmondson-Jones, Will Sullivan, Guillaume Cartron
"Don't keep me waiting": estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes. Blood advances 8 (13) (2024)
Gemma Elizabeth Shields, Paul Clarkson, Ash Bullement, Samuel Wagner, Mark Wilberforce, Tracey M Farragher, Arpana Verma, Linda M Davies
Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature. PharmacoEconomics (2024)
Ash Bullement, Matthew D Stevenson, Gianluca Baio, Gemma Elizabeth Shields, Nicholas R Latimer
A Systematic Review of Methods to Incorporate External Evidence into Trial-Based Survival Extrapolations for Health Technology Assessment. Medical decision making : an international journal of the Society for Medical Decision Making (2023)
Simone Critchlow, Ash Bullement, Simon J Crabb, Robert J Jones, Katerina Christoforou, Amerah Amin, Ying Xiao, Venediktos Kapetanakis, Ágnes Benedict, Jane Chang, Mairead Kearney, Anthony Eccleston
Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future oncology (London, England) (2023)
Leanne Hamerton, Kelly Gomes, Ronan Fougeray, Emma S Knowles, Marta Vargas Gomes, Ole Hauch, Ash Bullement
A UK cost-effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers. Future oncology (London, England) 19 (9) (2023)
Leanne Hamerton, Kelly Gomes, Ronan Fougeray, Emma S Knowles, Marta Vargas Gomes, Ole Hauch, Ash Bullement
A UK cost-effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers. Future oncology (London, England) 19 (9) (2023)
Holly L Cranmer, Gemma Elizabeth Shields, Ash Bullement
An Investigation into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology. Applied health economics and health policy (2023)
L Hamerton, K Gomes, R Fougeray, Emma S Knowles, M Vargas Gomes, Ole Hauch, Ash Bullement
A UK cost-effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers. Future oncology (London, England) (2023)
Leanne Hamerton, Kelly Gomes, Ronan Fougeray, Emma S Knowles, Marta Vargas Gomes, Ole Hauch, Ash Bullement
A UK cost-effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers. Future oncology (London, England) 19 (9) (2023)
Ash Bullement, Emma S Knowles, Pronabesh DasMahapatra, Talaha M Ali, Ron Preblick
Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States. PharmacoEconomics - open 5 (4) (2021)
Ash Bullement, Emma S Knowles, Merel Langenfeld, Gil Reynolds Diogo, Jameel Nazir, Daniel Eriksson
An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA). Open access rheumatology : research and reviews 13 (2021)
Gemma Elizabeth Shields, Rebekah Pennington, Ash Bullement, Stuart James Wright, Jamie Elvidge
Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time. PharmacoEconomics (2021)
Ash Bullement, Holly L Cranmer, Gemma Elizabeth Shields
A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments. Applied health economics and health policy 17 (6) (2020)
Holly L Cranmer, Gemma Elizabeth Shields, Ash Bullement
A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology. Journal of medical economics 23 (10) (2020)
Ash Bullement, Tanja Podkonjak, Mark J Robinson, Eugene Benson, Ross Selby, Anthony James Hatswell, Gemma Elizabeth Shields
Real-world evidence use in assessments of cancer drugs by NICE. International journal of technology assessment in health care (2020)
Ash Bullement, Yang Meng, Miranda Cooper, Dawn Lee, Tara Louise Harding, Chris O'Regan, Raquel Aguiar-Ibanez
A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available? Journal of medical economics 22 (3) (2018)